Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
300181 Zhejiang Jolly Pharmaceutical
- 16.52
- +0.46+2.86%
Market Closed Dec 20 15:00 CST
11.59BMarket Cap22.38P/E (TTM)
16.63High15.89Low116.91KlotVolume16.06Open16.06Pre Close191.82MTurnover1.95%Turnover Ratio30.26P/E (Static)701.39MShares18.5052wk High4.46P/B9.93BFloat Cap7.9152wk Low19.27Limit Up601.08MShs Float18.50Historical High12.85Limit Down4.61%Amplitude1.02Historical Low0.45Dividend TTM16.41Avg Price45.92KlotAsk2.72%Div YieldTTM100Lot Size68.01KlotBid
Zhejiang Jolly Pharmaceutical News
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Seems To Use Debt Quite Sensibly
Jolly Pharmaceutical to Take Controlling Stake in Lingyi Biotech in Cooperation Deal; Shares Up 3%
Zhejiang Jolly Pharmaceutical (300181.SZ): Signed a global strategy cooperation framework agreement with Lingyi Biotechnology.
On November 20th, Jolly Pharmaceutical (300181.SZ) announced that the company has signed a "Strategic Cooperation Framework Agreement" with Lingyi (Hangzhou) Biotechnology Co., Ltd. According to the agreement, the two parties will establish a long-term and in-depth strategic cooperation relationship. The main areas of cooperation include equity cooperation, research and development cooperation, sales cooperation, and product cooperation. In terms of equity cooperation, Jolly Pharmaceutical will increase its capital to become the second largest shareholder of Lingyi Biotech (Series A round). In terms of research and development cooperation, the two parties will jointly develop innovative drugs for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Jumps 6.5% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Zuoli Pharmaceuticals: third quarter report 2024
Zhejiang Jolly Pharmaceutical (300181.SZ) plans to launch an employee stock ownership plan in 2024.
Zhejiang Jolly Pharmaceutical (300181.SZ) released the 2024 employee stock ownership plan (draft), the employee stock ownership plan is expected to raise...
Zhejiang Jolly Pharmaceutical (300181.SZ) plans to launch a restricted stock incentive plan for 2024.
Zhejiang Jolly Pharmaceutical (300181.SZ) released the 2024 restricted stock incentive plan (draft), intending to incentivize...
Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Surges 7.5%; Individual Investors Who Own 49% Shares Profited Along With Insiders
Potential Upside For Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Not Without Risk
Zhongtai Securities: Short-term performance pressure in the traditional Chinese medicine sector, with main focus on improving quality and efficiency.
Against the backdrop of high base numbers in H1 2023, the traditional chinese medicine sector's performance is under short-term pressure. With the fading of the base effect and the arrival of the peak season in autumn and winter, the sector's performance is expected to gradually improve.
China Merchants Securities: Profit performance is better than revenue, and top OTC brands have stronger resilience.
In the first half of 2024, high-end scarce resources and traditional Chinese medicine OTC enterprises with brand and channel barriers performed well, while hospital-based traditional Chinese medicine enterprises were under short-term pressure due to industry policies and other factors.
Zuli Pharmaceuticals: Earnings Forecast for the First Three Quarters of 2024
Zhejiang Jolly Pharmaceutical (300181.SZ) has cumulatively repurchased 1.24% of the shares, with a total investment of 0.127 billion yuan.
Zhejiang Jolly Pharmaceutical (300181.SZ) announced that as of August 31, 2024, the company will trade through centralized bidding...
Could The Market Be Wrong About Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Given Its Attractive Financial Prospects?
Zhejiang Jolly Pharmaceutical: The regions that won the centralized procurement bids have basically achieved volume-based pricing and will develop 10 varieties of Wuling series.
①The company has seen both gains and losses in centralized procurement, for example, sales in centralized procurement areas have increased significantly compared to non-centralized procurement areas, but the company once lost the bid in the procurement of Bacillus Subtilis; ②Due to the reduction of sales expenses and other reasons, the net income of the company in the areas where it won the bid in centralized procurement has actually increased; ③Currently, the company's production capacity utilization rate of Trametes versicolor powder is relatively high and expansion projects for the second phase are underway, with future considerations for planning new production capacity.
Zhejiang Jolly Pharmaceutical (300181.SZ): Bailin capsule has completed the online listing in 28 provinces and has not been officially sold yet.
On August 16, Gelunhui reported that Zhejiang Jolly Pharmaceutical (stock code: 300181.SZ) has completed the network listing of Bailing Capsules in 28 provinces and has not yet been officially launched for sale.
Zhejiang Jolly Pharmaceutical (300181.SZ) has repurchased 0.4328 million shares for a total of 6.3996 million yuan.
On August 13th, Gelonhui announced that Zhejiang Jolly Pharmaceutical (300181.SZ) had implemented its first buyback through the stock repurchase dedicated securities account via centralized bidding trading. The number of shares repurchased by the company this time was 432,800 shares, accounting for 0.06% of the company's current total share capital. The highest fill price was 14.95 yuan/share, the lowest fill price was 14.70 yuan/share, and the total transaction amount was RMB 6,399,641 (excluding transaction fees). This buyback complies with the company's share repurchase plan and relevant laws and regulations.
Zhejiang Jolly Pharmaceutical (300181.SZ): Sales of out-of-hospital end mainly include sales of OTC end and internet plus-related end, accounting for a little over 10% of sales.
Zhejiang Jolly Pharmaceutical (300181.SZ) recently conducted investor relations activities regarding the growth of the outpatient terminal in the first half of this year. The company's outpatient terminal mainly includes OTC and internet-related sales, accounting for more than 10% of total sales. In the first half of this year, due to the relatively small overall base of OTC products, the growth rate was slightly faster than that of the inpatient terminal. The company attaches great importance to the sales of OTC products. Its focus in the future is to improve the acceptance of the outpatient terminal and enhance consumers' health education, with the aim of increasing the sales ratio of the outpatient terminal to at least 20%. Meanwhile, the company has also laid out its plan.
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Could Easily Take On More Debt
